COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients

Breast Cancer Research and Treatment

Volumn 125, Issue 3, 2011, Pages 671-685

  Van Nes, Johanna G H ^a   De Kruijf, Esther M ^a   Faratian, Dana ^b   Van De Velde, Cornelis J H ^a   Putter, Hein ^a   Falconer, Claire ^b   Smit, Vincent T H B M ^a   Kay, Charlene ^b   Van De Vijver, Marc J ^c   Kuppen, Peter J K ^a   Bartlett, John M S ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

COX2; Early breast cancer; Endocrine therapy; Prognostic and predictive factors

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER HORMONE THERAPY; CANCER SURGERY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CYCLOOXYGENASE 2; ENDOCRINE SYSTEM; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MODELS, STATISTICAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS;

EID: 79151477240     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0854-7     Document Type: Article

References (34)

1. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108 10.3322/canjclin.55.2.74 15761078
2. Early Breast Cancer Trialists' Collaborative Group 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
3. A Goldhirsch WC Wood RD Gelber, et al. 2007 Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann Oncol 18 1133 1144 1:STN:280:DC%2BD2svlvVSkuw%3D%3D 10.1093/annonc/mdm271 17675394 (Pubitemid 47244357)
4. RE Harris RT Chlebowski RD Jackson, et al. 2003 Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative Cancer Res 63 6096 6101 1:CAS:528:DC%2BD3sXnvVSitb8%3D 14522941
5. SA Khuder AB Mutgi 2001 Breast cancer and NSAID use: a meta-analysis Br J Cancer 84 1188 1192 1:CAS:528:DC%2BD3MXkt1Olurc%3D 10.1054/bjoc.2000.1709 11336469 (Pubitemid 32511336)
6. PH Rolland PM Martin J Jacquemier, et al. 1980 Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells J Natl Cancer Inst 64 1061 1070 1:CAS:528:DyaL3cXktVGmurY%3D 6767871
7. GP Boland IS Butt R Prasad, et al. 2004 COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ Br J Cancer 90 423 429 1:CAS:528:DC%2BD2cXksl2lsQ%3D%3D 10.1038/sj.bjc.6601534 14735188 (Pubitemid 38250640)
8. C Costa R Soares JS Reis-Filho, et al. 2002 Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer J Clin Pathol 55 429 434 1:STN:280:DC%2BD38zhs1Wrsw%3D%3D 12037025
9. C Denkert KJ Winzer BM Muller, et al. 2003 Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma Cancer 97 2978 2987 1:CAS:528:DC%2BD3sXlt1Shtbo%3D 10.1002/cncr.11437 12784332 (Pubitemid 36676251)
10. BG Haffty Q Yang MS Moran, et al. 2008 Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation Int J Radiat Oncol Biol Phys 71 1006 1013 1:CAS:528:DC%2BD1cXnsFGhsLc%3D 10.1016/j.ijrobp.2007.11. 063 18262731
11. E Half XM Tang K Gwyn, et al. 2002 Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ Cancer Res 62 1676 1681 1:CAS:528:DC%2BD38XisVSisb4%3D 11912139
12. D Hwang D Scollard J Byrne E Levine 1998 Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer J Natl Cancer Inst 90 455 460 1:STN:280:DyaK1c7otVCltw%3D%3D 10.1093/jnci/90.6.455 9521170
13. LM Kelly AD Hill S Kennedy, et al. 2003 Lack of prognostic effect of Cox-2 expression in primary breast cancer on short-term follow-up Eur J Surg Oncol 29 707 710 1:STN:280:DC%2BD3srisVKhsw%3D%3D 10.1016/j.ejso.2003.07.001 14602487 (Pubitemid 37483941)
14. JK O'Connor J Avent RJ Lee, et al. 2004 Cyclooxygenase-2 expression correlates with diminished survival in invasive breast cancer treated with mastectomy and radiotherapy Int J Radiat Oncol Biol Phys 58 1034 1040 10.1016/j.ijrobp.2003.08.032 15001242 (Pubitemid 38314783)
15. K Park S Han E Shin, et al. 2006 Cox-2 expression on tissue microarray of breast cancer Eur J Surg Oncol 32 1093 1096 1:STN:280:DC%2BD28novVersA%3D%3D 10.1016/j.ejso.2006.05.010 16797158 (Pubitemid 44774393)
16. A Ristimaki A Sivula J Lundin, et al. 2002 Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer Cancer Res 62 632 635 1:CAS:528:DC%2BD38Xht1KrtLg%3D 11830510
17. KJ Schmitz R Callies J Wohlschlaeger, et al. 2006 Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu signalling pathways J Clin Pathol 59 685 691 1:CAS:528:DC%2BD28XotFehurY%3D 10.1136/jcp.2005.030650 16497869 (Pubitemid 44048775)
18. G Singh-Ranger A Jewell V Thomas K Mokbel 2004 Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers J Surg Oncol 88 100 103 10.1002/jso.20142 (Pubitemid 39536510)
19. RA Soslow AJ Dannenberg D Rush, et al. 2000 COX-2 is expressed in human pulmonary, colonic, and mammary tumors Cancer 89 2637 2645 1:CAS:528: DC%2BD3MXitFWisw%3D%3D 10.1002/1097-0142(20001215)89:12<2637::AID- CNCR17>3.0.CO;2-B 11135226 (Pubitemid 32011609)
20. G Spizzo G Gastl D Wolf, et al. 2003 Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival Br J Cancer 88 574 578 1:CAS:528:DC%2BD3sXht1Glurw%3D 10.1038/sj.bjc.6600741 12592372 (Pubitemid 36363367)
21. CJ Witton SJ Hawe TG Cooke JM Bartlett 2004 Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer Histopathology 45 47 54 1:STN:280:DC%2BD2czislaqsw%3D%3D 10.1111/j.1365-2559.2004.01898.x 15228443 (Pubitemid 38969561)
22. MP Zerkowski RL Camp BA Burtness, et al. 2007 Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome Cancer Invest 25 19 26 1:CAS:528:DC%2BD2sXnt1agsLw%3D 10.1080/07357900601128825 17364553 (Pubitemid 46423585)
23. RN Dubois SB Abramson L Crofford, et al. 1998 Cyclooxygenase in biology and disease FASEB J 12 1063 1073 1:CAS:528:DyaK1cXlvFWntbY%3D 9737710
24. LM McShane DG Altman W Sauerbrei, et al. 2005 Reporting recommendations for tumor marker prognostic studies J Clin Oncol 23 9067 9072 10.1200/JCO.2004.01.0454 16172462
25. BR Leyland-Jones CB Ambrosone J Bartlett, et al. 2008 Recommendations for collection and handling of specimens from group breast cancer clinical trials J Clin Oncol 26 5638 5644 10.1200/JCO.2007.15.1712 18955459
26. J Bartlett E Mallon T Cooke 2003 The clinical evaluation of HER-2 status: which test to use? J Pathol 199 411 417 1:CAS:528:DC%2BD3sXlt1Sgtrg%3D 10.1002/path.1354 12635130 (Pubitemid 36411216)
27. RL Camp LA Charette DL Rimm 2000 Validation of tissue microarray technology in breast carcinoma Lab Invest 80 1943 1949 1:STN:280: DC%2BD3M%2Foslamsg%3D%3D 10.1038/labinvest.3780204 11140706
28. KL Henriksen BB Rasmussen AE Lykkesfeldt, et al. 2007 Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays J Clin Pathol 60 397 404 10.1136/jcp.2005.034447 16775123 (Pubitemid 46596559)
29. T Kirkegaard J Edwards S Tovey, et al. 2006 Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 48 787 794 1:STN:280:DC%2BD283ptleqsw%3D%3D 10.1111/j.1365-2559. 2006.02412.x 16722926 (Pubitemid 43800937)
30. T Kirkegaard CJ Witton LM McGlynn, et al. 2005 AKT activation predicts outcome in breast cancer patients treated with tamoxifen J Pathol 207 139 146 1:CAS:528:DC%2BD2MXhtFKnsr7P 10.1002/path.1829 16088978 (Pubitemid 41404144)
31. D Faratian C Kay T Robson, et al. 2009 Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large-scale clinical studies: the TEAM Trial Experience Histopathology 55 5 587 593 10.1111/j.1365-2559.2009.03419.x 19912364
32. DA Turbin S Leung MC Cheang, et al. 2008 Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases Breast Cancer Res Treat 110 417 426 1:CAS:528:DC%2BD1cXosVOgt7c%3D 10.1007/s10549-007-9736-z 17912629 (Pubitemid 351962583)
33. Altman DG, Machin D, Bryant TN, Gardner MJ (2000) Statistics with confidence. British Medical Journal Books, Bristol
34. Early Breast Cancer Trialists' Collaborative Group 1998 Tamoxifen for early breast cancer: an overview of the randomised trials Lancet 351 1451 1467 10.1016/S0140-6736(97)11423-4 (Pubitemid 28227036)